% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hennrich:182301,
      author       = {U. Hennrich$^*$ and M. Eder$^*$},
      title        = {[177{L}u]{L}u-{PSMA}-617 ({P}luvicto{TM}): {T}he {F}irst
                      {FDA}-{A}pproved {R}adiotherapeutical for {T}reatment of
                      {P}rostate {C}ancer.},
      journal      = {Pharmaceuticals},
      volume       = {15},
      number       = {10},
      issn         = {1424-8247},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2022-02558},
      pages        = {1292},
      year         = {2022},
      note         = {#EA:W630#},
      abstract     = {In March 2022, [177Lu]Lu-PSMA-617 (PluvictoTM) was approved
                      by the FDA for the treatment of prostate cancer patients.
                      Until now, the approval has been limited to patients with
                      PSMA-positive metastatic castration-resistant prostate
                      cancer who have previously received other therapy options
                      (such as inhibition of the androgen receptor pathway and
                      taxane-based chemotherapy). [177Lu]Lu-PSMA-617, which
                      combines a PSMA-specific peptidomimetic with a therapeutical
                      radionuclide, is used in a radioligand therapy that
                      selectively delivers ionizing radiation to tumor cells,
                      causing their death, while sparing the surrounding healthy
                      tissue. In numerous clinical trials, the efficacy of
                      [177Lu]Lu-PSMA-617 was demonstrated.},
      subtyp        = {Review Article},
      keywords     = {PSMA (Other) / PluvictoTM (Other) / [177Lu]Lu-PSMA-617
                      (Other) / prostate cancer (Other) / radioligand therapy
                      (RLT) (Other) / theranostics (Other)},
      cin          = {W630 / FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)W630-20160331 / I:(DE-He78)FR01-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36297404},
      doi          = {10.3390/ph15101292},
      url          = {https://inrepo02.dkfz.de/record/182301},
}